MOTYS IND is Filed, Sales Training Begins

By now, you have seen the company-wide email from MK Kottke, Senior Director, Regulatory and Clinical Affairs, regarding the successful investigational new drug (IND) filing for MOTYS. MK thanked Alessandra Pavesio and the extended team on the project including Carl Flannery, Neill Pounder, John Rice, Scott “Sage” Seaman, Kelly Buddin, Drew Sullivan, Jonathan Han, Jason Siegfried and Peter Shaw.

All were critical to the success of the project, but MK was the captain of that team.

“MK is the one who actually put the plan together more than 18 months ago. She has orchestrated the collection of all the data, has checked every document, has authored way more content than she had ever signed up for, has verified every hyperlink, has kept every timeline and delivered not only our first IND, but one of outstanding quality,” said Alessandra. “An IND submission is a monumental milestone in the history of an organization. To think that this has been done quasi single handedly by MK is hard to believe, but MK does come from another planet. We are so lucky that she has chosen to land here with her spaceship.”

Also of note and occurring later this month, is training for members of the US Active Healing Therapies Sales Team with the introduction of MOTYS into the cash pay market, under human cell and tissue product guidelines. This begins with 18 reps on October 13-14.

“This training will be a live, Zoom hybrid where we have 11 reps coming into Raleigh and 7 reps attending via Zoom,” said Steven Moore, Director of Global Marketing for Amniotic & AHT, Global EXOGEN and HA Strategy. “In addition, we will have the respective reps’ Directors of Sales and Area Vice Presidents attending via Zoom. A host of corporate staff will also be attending live to lead, present and support this select group of reps.”

To hear more about the MOTYS launch from Steven, visit the Audiobiologics Podcast.